BioSpace News Archive

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Wells Fargo 2023 Healthcare Conference to be held September 6-8, 2023.

Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, announced that it will participate in the following investor conferences.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will present at the 2023 Wells Fargo Healthcare Conference at 3:45 p.m. Eastern Time on Thursday, September 7, 2023 in Boston.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in September.

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the first patients have been dosed in its ongoing REVERTIPF trial.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the hybrid H.C. Wainwright 25th Annual Global Investment Conference, which will be held September 11-13, 2023.

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, will present in the following September 2023 conferences.

Centogene N.V. announced that it has received a written notification from the Nasdaq Stock Market LLC dated August 30, 2023, indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market.

Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 11:00 a.m. ET in Boston, Mass.